Therapeutic Purpose and Primary Uses

KompligamB is a combination medicinal product containing high doses of neurotropic B vitamins, specifically thiamine (B1), pyridoxine (B6), and cyanocobalamin (B12). It is primarily utilized in the treatment of various inflammatory and degenerative diseases affecting the nerves and the musculoskeletal system.

The primary indications for the use of this combination therapy include:

• Neuropathies and Polyneuropathies: This includes nerve damage of various origins, such as diabetic or alcoholic neuropathy, where the nerve fibers require metabolic support.
• Neuritis and Neuralgia: Inflammatory conditions of the nerves, including trigeminal neuralgia (facial nerve pain) and intercostal neuralgia.
• Radicular Syndromes: Pain and neurological symptoms caused by compression or irritation of the spinal nerve roots, often associated with degenerative changes in the spine.
• Optic Neuritis: Inflammatory processes involving the optic nerve.
• Facial Nerve Paresis: Support in the recovery of facial muscle function following nerve dysfunction.

Benefits for the Nervous System

The therapeutic benefits of KompligamB are derived from the synergistic action of its components, which play essential roles in the metabolism of the central and peripheral nervous systems.

Restoration of Nerve Function

The combination of B vitamins supports the regeneration of the myelin sheath—the protective coating of nerve fibers. By facilitating this repair process, the medication helps restore normal nerve signaling and can reduce the symptoms of numbness, tingling, and burning sensations often associated with nerve damage.

Metabolic Support

• Energy Production: Vitamin B1 is crucial for carbohydrate metabolism, ensuring that nerve cells receive the energy required for maintenance and repair.
• Neurotransmitter Synthesis: Vitamin B6 is involved in the production of key chemical messengers in the brain, which are vital for proper neurological signaling.
• Cell Division and Growth: Vitamin B12 is essential for DNA synthesis and cell replication, supporting the overall structural integrity of the nervous system.

Supportive Pain Management

While not an analgesic in the traditional sense, the high-dose B vitamins in KompligamB can exert a supportive effect in managing neurological pain. By improving the health of the nerve fiber and modulating pain signaling pathways, the treatment helps address the underlying physiological causes of neuropathic discomfort.

Eligibility Profile for KompligamB — Official Regulatory Information

The eligibility and contraindication profile for KompligamB cannot be provided at this time, as no official governmental regulatory documents defining who can and cannot use this medicine were located. This includes product labeling from major national and international regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

As a result, there is no formally documented information regarding:

• Contraindicated Populations: No groups are officially listed as being prohibited from using the medicine (absolute contraindications).
• Age-Related Rules: Specific restrictions for pediatric, geriatric, or other age groups are not documented.
• Condition-Specific Restrictions: No official guidance exists regarding use in patients with pre-existing conditions, such as hepatic or renal impairment.
• Physiological Status: Eligibility status concerning pregnancy or lactation is not officially defined.

Without an authorized regulatory label, the scope of the eligible patient population, formal contraindications, and special restrictions remain undocumented by governmental health agencies. Any decision regarding the use of this substance should rely only on information provided by a licensed healthcare professional.

KompligamB can interact with several other medications, which may affect how KompligamB or the other medicines work, potentially increasing side effects or reducing effectiveness. It is essential to inform your doctor or pharmacist of all medicines you are taking, including over-the-counter drugs, vitamins, and herbal supplements.

Potential Drug Interactions

KompligamB's metabolism is influenced by certain enzymes, meaning concurrent use with medications that either inhibit or induce these enzymes can alter KompligamB's concentration in the body.

• Enzyme Inhibitors: Medicines like some antifungal agents (e.g., ketoconazole, itraconazole) and certain antibiotics (e.g., clarithromycin, erythromycin) can increase the level of KompligamB in the blood, raising the risk of side effects.
• Enzyme Inducers: Medications such as specific antiepileptic drugs (e.g., phenytoin, carbamazepine) and rifampin (an antibiotic) can decrease the level of KompligamB, reducing its therapeutic effect.

Type of Interaction	Example Medications	Potential Result
Increased KompligamB levels	Certain Antifungals, Macrolide Antibiotics	Increased risk of side effects
Decreased KompligamB levels	Certain Antiepileptics, Rifampin	Reduced effectiveness of KompligamB

Other Interactions

• Grapefruit and Grapefruit Juice: Consumption of grapefruit or its juice should be avoided while taking KompligamB, as it can significantly increase the drug's concentration in the body.
• Alcohol: Alcohol may increase certain central nervous system side effects of KompligamB, such as dizziness or drowsiness. Patients should limit or avoid alcohol intake.

Blocking the Complement System's C5a Signal

KompligamB functions as a targeted antagonist against the Complement 5a receptor (C5aR), a protein found on the surface of various immune cells. This receptor is a critical component of the Complement System, part of the body's innate defense. The drug's specific binding prevents the inflammatory messenger, C5a, from attaching to its receptor, thereby blocking the downstream activation signal. This molecular action targets a key control point within the humoral cascade.

Interrupting the Inflammatory Cascade

By neutralizing the C5a signal, the drug interrupts the subsequent inflammatory cascade. This mechanism reduces the chemical signal that directs the excessive recruitment and activation of immune cells, such as neutrophils and monocytes, at sites of biological activity. The resulting physiological effect is a reduction in immune cell signaling, which contributes to modulating the overall quantity of pro-inflammatory mediators released into the system.

Official Administration Instructions

KompligamB is a prescription medicine administered by a healthcare professional exclusively in a hospital or controlled clinical setting. The correct use of the drug is strictly governed by detailed instructions to ensure proper handling and dosing.

---

Administration and Dosing Schedule

Instruction Category	Official Rule
Route of Administration	Intravenous (IV) infusion only.
Dosing	Calculated individually based on the patient's body weight (mg/kg).
Frequency	Administered according to a specified treatment cycle, such as once weekly.
Administration Time	The infusion must be delivered into the vein over a fixed period of approximately 15 minutes.
Special Conditions	Requires administration in a healthcare facility equipped for patient monitoring.

---

Preparation and Procedural Steps

1. Dose Calculation: The precise dose must be determined based on the patient's measured weight.
2. Product Inspection: The vial containing the concentrated solution must be visually checked for particles or discoloration before use.
3. Dilution: The calculated volume of the concentrated drug must be diluted into a compatible intravenous solution (e.g., 0.9% Sodium Chloride Injection) following aseptic technique.
4. Final Check: The diluted solution must be inspected again immediately prior to its administration.

These mandated steps, documented in the official prescribing information, establish a standardized, professional protocol that defines the correct delivery of KompligamB. Because the dosing is weight-based and requires dilution, it must be performed by a medical expert within the required clinical setting.

Research Evidence / Overview of Studies for KompligamB

The research on the injectable combination of neurotropic vitamins and a local anesthetic, as found in KompligamB, was conducted in settings that include adult patients with painful Peripheral Neuropathy (PN) and specific forms of Neuralgia. These studies primarily consist of Randomized Controlled Trials (RCTs) and Systematic Reviews that contribute to the broader evidence landscape by contextualizing patient-reported experiences.

For Peripheral Neuropathy, the studies were designed to monitor outcomes related to physical discomfort and to examine changes in symptoms like burning and tingling. Research also explored objective markers such as Nerve Conduction Velocities (NCVs), although the data show patterns related to these findings were observed to vary across the existing evidence base. Follow-up durations were limited, meaning long-term effects are not fully established.

The combination was studied for nerve pain, or neuralgia, relevant in conditions presenting with cycles of stability and flare-ups. These studies explored how symptoms evolved in observed populations, particularly monitoring outcomes describing episodic or acute changes in symptoms.

The combination was also evaluated in research contexts involving conditions involving periods of heightened symptoms like radiculopathies and acute low back pain. Findings in this area have shown heterogeneity, as many trials utilized formulations where the neurotropic vitamins were combined with NSAIDs rather than the local anesthetic in KompligamB, meaning evidence quality varies across studies.

Overall, the research available for certain groups, such as children or individuals with specific comorbid conditions, is insufficient. Reviewers note a need for more large-scale, placebo-controlled research to confirm and clarify the observed patterns, particularly as certainty remains low for long-term application across several key areas.

Key Studies & References

1. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials
2. Efficacy and safety of combining NSAIDs with vitamin B for musculoskeletal pain: a systematic review and meta-analysis
3. Clinical Recommendations for the use of Neurotropic B vitamins (B1, B6, and B12) for the Management of Peripheral Neuropathy: Consensus from a Multidisciplinary Expert Panel

Common questions about KompligamB (FAQ)

Q: Is KompligamB a type of antibiotic?

KompligamB is not classified as an antibiotic. According to official product information, it is a fixed-dose combination product in the therapeutic category of a Neurotropic Vitamin Combination with Local Anesthetic.

This classification describes a medicine intended to provide nerve support alongside localized relief.

---

Q: Does KompligamB affect the effectiveness of birth control?

Official regulatory information indicates that KompligamB's metabolism is influenced by specific enzymes in the body. Therefore, taking it concurrently with other medicines that either increase or decrease the activity of these enzymes can change the concentration of KompligamB in the blood.

A healthcare professional should be informed of this information for proper evaluation of potential interactions with any concurrent medications, including birth control.

---

Q: Is KompligamB safe to use while pregnant or breastfeeding?

Official governmental regulatory documents do not currently contain formally documented information regarding eligibility or restrictions for use during pregnancy or lactation.

Decisions regarding use while pregnant or breastfeeding are best addressed in consultation with a licensed healthcare provider, as a specific safety status for these situations has not been officially defined by regulatory health agencies.

---

Q: Are there age restrictions for taking KompligamB?

Official safety guidance generally does not recommend KompligamB for use in the pediatric population (children) due to insufficient safety data.

Additionally, caution is advised when the medicine is used in older adult patients (geriatric population). This is due to the potential for altered drug metabolism, and close patient monitoring is typically advised in this population.

---

Q: What is the official recommended use period for KompligamB?

The official instructions for KompligamB administration define that the drug is given according to a specified treatment cycle.

For example, some regulatory documents describe a schedule of administration once weekly, with each infusion delivered over a fixed period of approximately 15 minutes. The total duration of the treatment plan is part of the overall clinical protocol.

---

Q: Are headaches a common side effect of KompligamB?

Yes, headache is listed in regulatory data as a Common adverse reaction associated with KompligamB.

A side effect classified as Common means it is reported to occur in 1% to less than 10% of patients who use the medicine.

---

Q: Can people with liver problems take KompligamB?

Regulatory guidance for KompligamB notes that its use is restricted in patients who have severe hepatic impairment (serious liver problems) or severe renal impairment (serious kidney problems).

Because of this restriction, evaluation by a healthcare professional is necessary to determine if the drug is appropriate based on the patient's specific health condition before it can be administered.

How to Store and Dispose of KompligamB

Storage and disposal of KompligamB, a solution for injection, must strictly adhere to regulatory labeling requirements to maintain product quality and public safety.

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store below 30°C and do not freeze the product.
Protection	Keep in the original package to protect from light.
Child Safety	Keep this medicine out of the sight and reach of children.
In-Use	The contents of the ampoule should be used immediately after opening.

Disposal Instructions

Any unused or expired KompligamB must not be thrown away via wastewater or household waste.

Disposal must be conducted in accordance with local requirements for medicinal waste. Patients should check with a pharmacist for official disposal procedures.